Forest plot analysis demonstrated that tumours expressing low levels of the metagene derived from ANXA1 (dichotomised at the median) showed a benefit from trastuzumab (multivariate: hazard ratio [HR] = 0.16 [95% CI 0.05–0.5] p = 0.002; fdr = 0.03). Here, ANXA1 is linked to neoplasm.